Co-Diagnostics

Co-Diagnostics Acquisitions (Net)

The Acquisitions (Net) of Co-Diagnostics (CODX) as of Nov 20, 2026 is 17.82 M USD. In the previous year, Acquisitions (Net) was 16.75 M USD — a change of 6.36% (higher).

Acquisitions (Net)

17.82 MUSD

YoY

6.36%

Last updated:

Acquisitions (Net) of Co-Diagnostics is 2024 17.82 M USD. Acquisitions (Net) of Co-Diagnostics was 2023 16.75 M USD. It decreases by 6.36% higher compared to the previous year.

The Co-Diagnostics Acquisitions (Net) history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Acquisitions (Net)
Date
Acquisitions (Net)
Jan 1, 2017
-60,000.00 USD
Jan 1, 2018
-340,000.00 USD
Jan 1, 2019
-320,000.00 USD
Jan 1, 2020
-5.05 M USD
Jan 1, 2021
4.77 M USD
Jan 1, 2022
-56.74 M USD
Jan 1, 2023
16.75 M USD
Jan 1, 2024
17.82 M USD
The Co-Diagnostics Acquisitions (Net) history
YEARAcquisitions (Net)YoY
17.82 MUSD+6.36%
16.75 MUSD-129.53%
-56.74 MUSD-1,289.52%
4.77 MUSD-194.46%
-5.05 MUSD+1,478.13%
-320,000.00USD-5.88%
-340,000.00USD+466.67%
-60,000.00USD—
0.00USD-100.00%
10,000.00USD-105.56%
-180,000.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Co-Diagnostics Stock analysis

What does Co-Diagnostics do? Co-Diagnostics, Inc. develops and sells diagnostic tests using proprietary reagents and a test design system for diseases and pathogens including tuberculosis, drug-resistant tuberculosis, hepatitis B and C, malaria, dengue, HIV, and Zika virus. The company also markets self-contained lab systems (MDx devices) from other manufacturers. Its products are sold to laboratories and healthcare providers for molecular testing of organisms and genetic diseases, automating complex procedures in test development and administration. The firm generates revenue through the sale of diagnostic reagents, validated tests, and MDx devices. The company's diagnostic technology focuses on nucleic acid detection and analysis, enabling molecular testing for various pathogens and genetic conditions. Its proprietary system allows for the design and validation of tests in-house, which are then marketed to healthcare institutions. Revenue streams include reagent sales, test kits, and equipment from partner manufacturers. Co-Diagnostics, Inc. targets laboratories and healthcare providers as key customers for its diagnostic solutions. The firm's products are designed to streamline molecular testing processes, reducing the complexity of traditional methods. This approach supports the company's revenue model based on direct sales of its proprietary tests and complementary equipment. Co-Diagnostics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Co-Diagnostics stock

Acquisitions (Net) of Co-Diagnostics is 17.82 M USD in 2024.

Acquisitions (Net) of Co-Diagnostics changed from 16.75 M USD to 17.82 M USD, representing a 6.36% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Acquisitions (Net) Co-Diagnostics since 2006 – with annual values, charts, and detailed analysis.

Net acquisitions represent the cash spent on acquiring other businesses, net of divestitures. Large acquisitions can transform a company's growth trajectory.

Acquisitions (Net)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Acquisitions (Net)'s Co-Diagnostics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Co-Diagnostics

All Key Metrics — Co-Diagnostics